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ABSTRACT
Objective: To examine the length of time between
receiving funding and publishing the protocol and
main paper for randomised controlled trials.
Design: An observational study using survival
analysis.
Setting: Publicly funded health and medical research
in Australia.
Participants: Randomised controlled trials funded by
the National Health and Medical Research Council of
Australia between 2008 and 2010.
Main outcome measures: Time from funding to the
protocol paper and main results paper. Multiple
variable survival models examining whether study
characteristics predicted publication times.
Results: We found 77 studies with a total funding of
$A59 million. The median time to publication of the
protocol paper was 6.4 years after funding (95% CI 4.1
to 8.1). The proportion with a published protocol paper
8 years after funding was 0.61 (95% CI 0.48 to 0.74).
The median time to publication of the main results
paper was 7.1 years after funding (95% CI 6.3 to 7.6).
The proportion with a published main results paper
8 years after funding was 0.72 (95% CI 0.56 to 0.87).
The HRs for how study characteristics might influence
timing were generally close to one with narrow CIs, the
notable exception was that a longer study length
lengthened the time to the main paper (HR=0.62 per
extra study year, 95% CI 0.43 to 0.89).
Conclusions: Despite the widespread registration of
clinical trials, there remain serious concerns of trial
results not being published or being published with a
long delay. We have found that these same concerns
apply to protocol papers, which should be publishable
soon after funding. Funding agencies could set a target
of publishing the protocol paper within 18 months of
funding.
INTRODUCTION
Randomised controlled trials (RCTs) repre-
sent the gold standard when evaluating
healthcare interventions, mainly because
they minimise selection bias.1 Policymakers
often depend on the published results from
RCTs and systematic reviews based on RCTs
to learn about the efﬁcacy of interventions
and to apply the ﬁndings in health policy.2
Previous research has found 30–50% of clin-
ical trial results do not get published, even
years after completion of the project.3–7 This
missing research is a large part of the overall
‘waste in research’, with the estimate that
85% of current research investment is
wasted.8
National Health and Medical Research
Council (NHMRC) Project Grants are the
biggest source of funding in Australia for
clinical trials. Project Grants aim to support
individual researchers as individuals or small
teams for a deﬁned project from 1 to 5 years.
Applications are extensive, including sections
on past funding, budget and progress
reports, but the key sections are the research-
ers’ track records and the nine-page detailed
background and research plan. Applications
for funding large clinical trials are generally
peer reviewed by a separate panel of experts
who only consider clinical trials.
The NHMRC have supported policies to
improve clinical trial reporting. In 2005, an
NHMRC grant helped establish the
Australian and New Zealand Clinical Trial
Registry (ANZCTR). In 2007, the NHMRC
published a code for the responsible
conduct of research, which stated that
researchers must register clinical trials and
have a responsibility to their colleagues and
the wider community to disseminate a full
account of their research as broadly as pos-
sible.9 In 2014, the NHMRC supported the
Strengths and limitations of this study
▪ We had a relatively small sample size of 77
studies.
▪ The protocol paper was examined as a time-
dependent intermediate event when examining
the time taken to publish the main paper.
▪ We did not contact authors to confirm publica-
tion dates.
Strand LB, et al. BMJ Open 2017;7:e012212. doi:10.1136/bmjopen-2016-012212 1
Open Access Research
group.bmj.com on March 26, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
Alltrials campaign, which calls for all past and present
clinical trials to be registered and their results reported.
To date, there is no NHMRC policy that mentions pub-
lishing research protocols.
The aim of this paper was to examine the time delay
between funding and publication for government-
funded RCTs in Australia. As well as the time to the pub-
lication of the main paper, we also examined the time to
a protocol paper. The main purpose of the protocol is
to predetermine the methods and primary outcomes, so
that issues such as outcome switching are reduced or at
least made explicit.10 Publishing a protocol paper also
allows others to see what research is ongoing and so
helps avoid duplicated research being funded. Ideally,
protocols would be published quickly, preferably soon
after the research is funded. We were also interested in
whether publication of a protocol paper was associated
with time to publication of the main paper and whether
there was an association between the study character-
istics (ie, funding amount, number of investigators and
number of participants) and time to publication.
METHODS
We examined studies funded by the NHMRC of
Australia. We combined data on the funding amount,
estimated number of research participants, number of
investigators and publication times in peer-reviewed jour-
nals of the protocol paper and main results paper. We
examined the time to publication of the protocol paper
and the main paper, and whether characteristics of the
study predicted these times.
Data collection
The NHMRC is Australia’s main funding body for
medical research. The NHMRC administers funding for
health and medical research on behalf of the Australian
Government, and provides funding for all areas of
research relevant to human health and medicine. This
study examined Project Grants which are the NHMRC’s
main scheme for individuals and teams of researchers
undertaking RCTs in any ﬁeld relevant to human
health. Applicants can apply for grants of up to 5 years
in duration.11
Every RCT should be registered. The three most rele-
vant trial registries for this study are the: ANZCTR,
International Standard Randomised Controlled Trial
Number (ISRCTN) and ClinicalTrials.gov. They repre-
sent a comprehensive source for information about
ongoing and completed publicly and privately funded
trials within and outside Australia. All three registries
use web-based systems to facilitate registration of clinical
trials.12–14 The registries include compulsory and
optional data items, and trials will not be registered
without completion of all compulsory data items and
approval by a human participant ethics review board.
Additional information about the registries is available
from their websites.12–14
Search strategy
We aimed to ﬁnd all RCTs funded by the NHMRC
between 2008 and 2010. We used these years to strike a
balance between examining recent data and allowing a
reasonable time for trial completion and publication.
We identiﬁed 77 RCTs by searching for the words ‘RCT’,
‘randomised’ and ‘trial’ in NHMRC documents available
on the NHMRC website (http://www.nhmrc.gov.au/
grants-funding/outcomes-funding-rounds). From the
same data we also extracted the funding amount ($A),
number of investigators and planned study duration. To
ﬁnd the number of participants and trial registration
number, we ﬁrst searched for the project name and princi-
pal investigator within ANZCTR. When a study could not
be located in ANZCTR, we searched for it within ISRCTN
and ClinicalTrials.gov. Some studies may have been regis-
tered in multiple registries, but we did not record this. The
data were entered into an Excel spreadsheet.
Two investigators (LBS and AGB) independently deter-
mined the publication status of each trial in January 2016.
To locate a protocol paper or main results paper, we
searched for the unique NHMRC project number and
the unique trial registration number in PubMed and in
Google Scholar. If we were unable to locate the papers by
this method, we searched for the name of the principal
investigator and the name of the project. We matched the
articles that were identiﬁed to the corresponding trial
using information about location, enrolment, study start
and completion dates, and outcome measures described
in the clinical trial registers. We also searched all available
NHMRC grant summaries from 2004 to 2012 (the last
year available from the NHMRC). If we found a protocol
paper, we searched all the papers that cited the protocol
paper to look for the main paper. Similarly, if we found
the main paper, we searched the text for mention of the
protocol paper. We only included protocols published in
peer-reviewed journals. The data collection process is
shown in ﬁgure 1.
Publication status and time to publication
For all published papers, we calculated time to publica-
tion from the date of the funding announcement.
For papers published online ahead of print, we used
the date the publication was available electronically.
For trials where we could not ﬁnd a protocol paper or a
main results paper, we used a censored follow-up time as
the last day we performed our search (31 January 2016).
We were interested in whether some trials were more
likely to be completed and wanted to examine whether
time to publication of the protocol paper and main results
paper was associated with funding amount, number of
investigators or participant numbers. We were also inter-
ested in whether publishing a protocol paper inﬂuenced
the time it took for the main results paper to be published.
Statistical analysis
Kaplan-Meier survival plots were used to show the time
to publication of protocol paper and main results paper.
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The y-axes in the plots were reversed to show the
increasing proportion of published papers over time. We
calculated the median time to publication and 95% CIs,
and the mean survival and 95% CI at the maximum
follow-up time of 8 years.
We used Cox proportional hazard models with time
since funding date as the time scale, and presented
results as HRs with 95% CIs. The predictor variables for
the publication of a protocol paper were funding
amount (per $A100K), number of investigators, project
duration and participant numbers (per 100). These vari-
ables were chosen as indicators of complexity that may
make a trial more difﬁcult to complete.
When examining the time to publication of the main
results paper, we added the protocol paper as a time-
dependent intermediate variable (ﬁgure 2).15 The alter-
native approach of using a binary variable for protocol
published (yes/no) ignores time and assumes the proto-
col was published on the funding date. This lengthens
the time between the protocol and main paper and
would bias the HR downwards.16 All analyses were per-
formed using R V.3.1.0.
Missing data
We were unable to ﬁnd four studies in any of the trial
registers, and so we did not have information on the
number of participants. We therefore randomly imputed
these missing numbers from the available participant
numbers. We created 10 imputed data sets and com-
bined the results using the ‘mitools’ package in R.17
Figure 1 Flow chart showing the data collection process. ANZCTR, Australian and New Zealand Clinical Trial Registry
NHMRC, National Health and Medical Research Council; RCT, randomised controlled trial.
Figure 2 The three key events over time. Studies may go
straight from funding to main paper publication or first publish
a protocol paper, which is therefore a time-dependent
variable. The illustration shows how ignoring the timing of the
protocol lengthens the time between the protocol paper and
the main paper which would bias the HR downwards. The
thicker part of the arrow from protocol to main paper in the
right panel is the arrow length in the left panel.
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RESULTS
We found 77 studies with a total funding of ∼$A59
million (see online supplementary appendix for list of
studies). Forty-three studies published a protocol paper
and 39 studies published a main results paper (ﬁgure 3).
Thirty million dollars and 50% of the funding went to
studies that have not yet published the main results paper
during the mean follow-up time of 6.2 years.
Characteristics of the RCTs by publication status are in
table 1.
Time to publication
From the funding date, the median time to publication
of the protocol paper was 6.4 years (ﬁgure 4), with a
95% CI from 4.1 to 8.1 years. The estimated proportion
with a published protocol paper 8 years after funding
was 0.61 (95% CI 0.48 to 0.74). One protocol was pub-
lished before funding.
The median time to publication of the main results
paper was 7.1 years (ﬁgure 5), with a 95% CI 6.3 to 7.6.
The estimated proportion with a published main results
paper 8 years after funding is 0.72 (95% CI 0.56 to
0.87). As expected, shorter studies were generally pub-
lished faster.
Multivariable analysis
We found no evidence for an association between
funding amount, number of investigators or participant
numbers with time to publication of protocol paper or
main results (table 2). Publication of a protocol paper
was not associated with time to publication of the main
results paper. Project duration was not associated with
time to protocol paper, but not surprisingly longer pro-
jects took longer to publish their main results paper,
with a HR of 0.62 per extra year (95% CI 0.43 to 0.89).
DISCUSSION
The median time to publishing a protocol paper from
NHMRC-funded research was 6.4 years after funding.
The median time to publication of the main results
paper was 7.2 years, well beyond the duration of funding
for NHMRC grant schemes. It is hard to understand the
reasons for these delays, because the study design
should largely be ﬁnalised at the time the researchers
receive funding, and a key criteria the NHMRC uses for
funding research is the feasibility of the project and the
investigators’ track record.18 Some delays may be due to
protracted peer review, which is no fault of the investiga-
tors.19 Other delays outside the investigators’ control are
sponsor termination and contractual issues.20
Publishing a protocol
Publishing a protocol early increases transparency and
gives the research community and the public a better
idea of ongoing studies. Protocols are often included in
systematic reviews or assist in development of prospective
meta-analyses, and can be particularly important for
research questions with little current evidence. While
some journals (eg, BMJ Open) will not accept protocol
papers if the data collection has concluded, there are
few guidelines on the timing of the publication of proto-
col paper in relation to funding or initiation of the
study. While there is an established guideline for the
reporting of a protocol,21 these only cover the content
and not the timing of protocol papers. The guidelines
could be extended to include a recommended target
date for publication after funding, or after ethics
approval for unfunded studies. A period of 18 months
after funding seems a sensible target. This time allows
researchers to transfer the information from the grant
application into the protocol format and allows time for
Figure 3 Flow chart showing publication status (protocol
and main paper) of the 77 funded studies.
Table 1 Characteristics of the randomised controlled
trials funded by the National Health and Medical Research
Council (NHMRC) Project Grants 2008–2010 by
publication status of main results paper
Main results paper published
Yes No
Characteristic Mean SD Mean SD
Funding amount
($1000)
756 539 788 509
Participant
numbers
562 680 545 1049
Median IQR Median IQR
Number of
investigators
5 4–6 5 4–6
Project duration
(years)
4 4–5 5 4–6
Protocol paper n Per cent n Per cent
Yes 20 51 23 61
No 19 49 15 39
Total 39 51 38 49
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peer review. Delays due to peer review could be avoided
by adding the protocol to a clinical trial registry.
Funding agencies such as the NHMRC could mandate a
target and withhold further funding if the protocol is
not published or at least submitted to a journal to
provide a clear incentive to publish the protocol. There
is a precedent for this, as the UK National Institute for
Health Research include in their funding contract that a
publicly available ﬁnal report must be submitted, and
this agency has a 98% publication rate.22
Current editorial processes at many journals mean it is
now much harder to get an RCT published without a
protocol, and so the problem we identiﬁed may be a
historic concern. However, the median time to protocol
paper was 7.3 years for studies funded in 2008, 3.9 years
for studies funded in 2009 and 6.0 years for studies
funded in 2010. So our data do not show clear signs of
improvement between 2008 and 2010.
Predictors of publication timing
Our sample size was relatively small, but the HRs for
how study characteristics might inﬂuence timing were
generally close to one with narrow CIs (table 2), which
suggests that the issues with timely publication are
common to large and small studies. The two exceptions
were study length and protocol paper. The mean HR for
Figure 4 Kaplan-Meier survival
curve (and 95% CIs as dashed
lines) for time from funding to
protocol paper published (n=77).
Horizontal lines on the survival
curve indicate censoring.
Figure 5 Kaplan-Meier survival
curves (and 95% CIs as dashed
lines) for time from funding to
main paper published for all
papers combined (left) and split
into relatively long and short
studies by median study length
(right; n=77). Horizontal lines on
the survival curves indicate
censoring.
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the protocol paper is <1, suggesting that publishing a
protocol slows the time to the main paper. This could be
because not having a protocol paper allows authors to
focus on statistically signiﬁcant results that may not have
been the primary outcome, and there is a bias towards
journals accepting papers with statistically signiﬁcant
results,23 and it generally takes longer to publish nega-
tive results.24 However, the CIs around the HR for the
protocol were wide, and a larger study is needed to
examine this potential association.
Previous studies
Our results are similar to related studies. A large study
of US RCTs found that only 36% had published their
results within 2 years of study completion7 and another
US study of clinical trials found that only 46% were pub-
lished within 30 months of trial completion.4 These
results and ours highlight the serious problem of
missing research and the timeliness of completing
studies. Registering trials has been an important step in
avoiding the waste of missing research, but it has not
solved the problem as there are many registered rando-
mised trials that remain unpublished.
Ours is the ﬁrst study to use Australian data and the
ﬁrst to additionally examine the protocol paper.
Limitations
There are a number of limitations. Our sample size
was relatively small compared with related studies. We
did not email authors to conﬁrm publication status,
but a related study found that emailing authors did
not provide much additional information.4 Our search
to identify RCTs would have missed studies that did
not include the three phrases we searched for in their
title.
CONCLUSIONS
In a time when there is very high competition for scarce
research funds, we found that both the protocol paper
and the results of clinical trials are not being published
in a timely fashion. Funding bodies need to focus
more on the outputs from research and timely publi-
cation of a protocol paper should be the ﬁrst milestone
to assess whether trials will produce results which
can be added to the body of evidence used for medical
decision-making.
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